Celldex Therapeutics, Inc. (CLDX) Financials
CLDX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 868.8 million | 30.2 million |
2023-12-31 | 465.6 million | 36.5 million |
2023-09-30 | 280.3 million | 33.5 million |
2023-06-30 | 299.3 million | 21.8 million |
CLDX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -41.0 million | 7.2 million |
2023-12-31 | -33.2 million | 7.2 million |
2023-09-30 | -19.2 million | 7.1 million |
2023-06-30 | -27.6 million | 5.2 million |
CLDX Net Income
No data available :(
CLDX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 819.1 million | - | 2.1 million |
2023-12-31 | 421.7 million | - | 2.5 million |
2023-09-30 | 235.3 million | - | 2.8 million |
2023-06-30 | 252.7 million | - | 3.3 million |
CLDX Shares Outstanding
CLDX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 344000 | 30.9 million | 9.1 million | - |
2023-12-31 | 666000 | 29.7 million | 8.8 million | - |
2023-09-30 | 157000 | 34.5 million | 8.2 million | - |
2023-06-30 | 410000 | 26.3 million | 7.2 million | - |
CLDX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 156000 | 775000 |
2023-12-31 | 4.1 million | 759000 |
2023-09-30 | 1.5 million | 767000 |
2023-06-30 | 268000 | 756000 |
CLDX
Price: $38.21
52 week price:
Earnings Per Share: -2.86 USD
P/E Ratio: -13.41
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 345800
Ebitda: -30.7 millionMarket Capitalization: 2.6 billion